Drug intelligence / Profile preview

CPC212

Development stage: Preclinical
Lead developer: Alephoson
Modality: Small Molecules
Administration: Ophthalmic

Overview

CPC212 is a preclinical-stage small molecule therapeutic candidate developed by Alephoson for the treatment of non-infectious uveitis (NIU), including both anterior and posterior forms. The drug is developed using Alephoson's proprietary Cell-Penetrating Complex (CPC) technology, which is designed to enhance the delivery of therapeutic agents across biological barriers, specifically for ocular applications. As of 2024, the specific molecular target and mechanism of action for CPC212 have not been publicly disclosed by the sponsor.

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on CPC212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPC212.

Explore the full profile